S
Sanjay S. Patel
Researcher at Cornell University
Publications - 39
Citations - 1264
Sanjay S. Patel is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 13, co-authored 30 publications receiving 767 citations. Previous affiliations of Sanjay S. Patel include Brigham and Women's Hospital & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City.
Alain C. Borczuk,Steven P. Salvatore,Surya V. Seshan,Sanjay S. Patel,James B. Bussel,Maria Mostyka,Sarah S. Elsoukkary,Bing He,Claudia Del Vecchio,Francesco Fortarezza,Federica Pezzuto,Paolo Navalesi,Andrea Crisanti,Mary Fowkes,Clare Bryce,Fiorella Calabrese,Mary Beth Beasley +16 more
TL;DR: COVID-19 pneumonia is a heterogeneous disease (tracheobronchitis, DAD, and vascular injury), but with consistent features in three centers, with Viral infection in areas of ongoing active injury contributes to persistent and temporally heterogeneous lung damage.
Journal ArticleDOI
Implications of the tumor immune microenvironment for staging and therapeutics.
Janis M. Taube,Jérôme Galon,Jérôme Galon,Jérôme Galon,Lynette M. Sholl,Scott J. Rodig,Tricia R. Cottrell,Nicolas A. Giraldo,Alexander S. Baras,Sanjay S. Patel,Robert A. Anders,David L. Rimm,Ashley Cimino-Mathews +12 more
TL;DR: The key components of the tumor microenvironment are summarized, an overview of and the challenges with PD-L1 antibodies and assays are presented, and newer candidate biomarkers, such as CD8+ cell density and mutational load are addressed.
Journal ArticleDOI
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Philippe Armand,Yi-Bin Chen,Robert A. Redd,Robin Joyce,Jad Bsat,Erin Jeter,Reid W. Merryman,Kimberly C. Coleman,Parastoo B. Dahi,Yago Nieto,Ann S. LaCasce,David C. Fisher,Samuel Y. Ng,Oreofe O. Odejide,Arnold S. Freedman,Austin I. Kim,Jennifer L. Crombie,Caron A. Jacobson,Eric D. Jacobsen,Jeffrey L. Wong,Sanjay S. Patel,Jerome Ritz,Scott J. Rodig,Margaret A. Shipp,Alex F. Herrera +24 more
TL;DR: In this paper, the authors conducted a multicohort phase 2 study of pembrolizumab in patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy.
Journal ArticleDOI
Immunoregulatory roles of versican proteolysis in the myeloma microenvironment
Chelsea Hope,Simon J. Foulcer,Justin C. Jagodinsky,Sarah X. Chen,Jeffrey L. Jensen,Sanjay S. Patel,Catherine P. Leith,Ioanna G. Maroulakou,Natalie S. Callander,Shigeki Miyamoto,Peiman Hematti,Suneel S. Apte,Fotis Asimakopoulos +12 more
TL;DR: The interplay between stromal cells and myeloid cells in the myeloma microenvironment generates versikine, a novel bioactive damage-associated molecular pattern that may facilitate immune sensing ofMyeloma tumors and modulate the tolerogenic consequences of intact VCAN accumulation.
Journal ArticleDOI
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative
Sanjay S. Patel,Sanjay S. Patel,Jason L. Weirather,Mikel Lipschitz,Ana Lako,Pei-Hsuan Chen,Gabriel K. Griffin,Philippe Armand,Margaret A. Shipp,Scott J. Rodig +9 more
TL;DR: Using multiplex immunofluorescence microscopy, with digital image analysis, it is found that cHL is highly enriched for non-T-regulatory, CTLA-4-positive T-cells, as compared to reactive lymphoid tissues, that outnumber PD-1- and LAG-3-positiveT-cells.